Beginning in 2018 and through 2021, CytoDyn and its former CEO Nader Pourhassan told investors repeatedly that a clinical trial had successfully demonstrated the effectiveness of an experimental ...

PORTLAND, Ore. (KOIN) – The former CEO of a Vancouver-based company who promised a drug that could treat HIV and potentially COVID-19 was indicted Tuesday on federal charges of defrauding investors.

CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PTVANCOUVER, Washington, May 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn ...

A federal jury Monday convicted the former chief executive for local biotechnology company CytoDyn, along with the head of the company’s regulatory agent to the U.S. Food and Drug Administration, for ...

CytoDyn's Phase 2 study in mCRC (NCT06699836), now underway, is enrolling 60 participants who will be tested with the LifeTracDx ® blood test at multiple-time points over the course of the trial.

CytoDyn’s efforts to get leronlimab past the regulatory finish line in any indication has been a saga—including an incident in which the biotech sent the wrong data sets to the FDA. But now, the ...

This is a livestream presentation. Attendees are advised to log in ahead of the start time. The Company will host a live Q&A session during the webcast; questions may be submitted in advance to ...

“We are encouraged by the continued progress being made as we advance leronlimab and explore its potential applications across solid tumors,” said Jacob Lalezari, M.D., CEO of CytoDyn. “The research ...

While Nader Pourhassan, the chief executive of drug maker CytoDyn, filed his intention to sell nearly $17 million of his company’s shares last Thursday, he was simultaneously pitching the same CytoDyn ...

VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a ...

I have seen some holdouts claiming CytoDyn might still use CD12 results to get some kind of approval. I show what's implied in CytoDyn's post hoc analysis, and it's not pretty. I also show why there's ...